1. mikecontreras2017
2. kinderreadypuent
3. russawye9
4. kevinkev78
5. xenstuff
1.kevinkev78 03/01/2018
argenx reports fourth quarter business update and full year 2017 financial results
2.xenstuff 01/29/2018
already close to the target
3.toddy709086 04/24/2018
argenx to present complete data from the Phase 2 proof-of-concept trial of efgartigimod (ARGX-113) in generalized myasthenia gravis at American Academy of Neurology (AAN) Annual Meeting
4.kevinkev78 01/29/2018
HEY WoW! Loving the chart
5.mikecontreras2017 04/10/2018
SunTrust Robinson Humphrey initiates as a buy, $125PT
6.xenstuff 03/22/2018
Announces the addition of a new pipeline candidate, ARGX-117, targeting the complement cascade with therapeu…
7.kinderreadypuent 01/29/2018
JMP Securities raises price target to $87 from $74
8.kevinkev78 06/20/2018
argenx reports interim data from first cohort of Phase 2 proof-of-concept clinical trial of efgartigimod for the treatment of pemphigus vulgaris
9.xenstuff 04/12/2018
argenx to receive third preclinical milestone payment from collaboration with LEO Pharma - Milestone associated with CTA approval for ARGX-112
10.mikecontreras2017 01/29/2018
{Image}
NEW since the last time you visited this board.
Currently a TOP 10 POST for this board.
Currently a TOP 5 RESEARCHER for this board.
Specific post has replies to it.
A Researcher you are currently FOLLOWING
Other Researchers rate this post HIGH
Other Researchers rate this post LOW